UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d)
of the
Securities Exchange Act of 1934
Date of
Report (Date of earliest event reported): June 10, 2009
ORAMED
PHARMACEUTICALS INC.
(Exact
name of registrant as specified in its charter)
|
Nevada
(State
or other jurisdiction
of
incorporation)
|
000-50298
(Commission
File Number)
|
98-0376008
(IRS
Employer
Identification
No.)
|
Hi-Tech
Park 2/5 Givat Ram
PO
Box 39098
Jerusalem,
Israel 91390
(Address
of principal executive offices and zip code)
Registrant’s
telephone number, including area code: 972-2-566-0001
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
o Written communications
pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
o Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
ITEM
7.01 REGULATION
FD DISCLOSURE
On June
10, 2009, Oramed Pharmaceuticals Inc. (the “Company”) issued a press release
announcing that it was chosen to present at the 8th National Life Science &
Technology Week ILSI-BIOMED Conference to be held in Israel. The presentation
will be given by Mr. Nadav Kidron, President and CEO of the Comapny, on Tuesday,
June 16th during the BioPharma Session at 12:30 p.m. (local time) at the David
Intercontinental Hotel in Tel-Aviv, Israel.
A copy of
the press release is attached to this Current Report on Form 8-K as Exhibit 99.1
and is incorporated herein by reference.
ITEM
9.01 FINANCIAL
STATEMENTS AND EXHIBITS.
|
(d)
|
Exhibits
|
|
99.1
|
Press
Release dated June 10, 2009
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
ORAMED PHARMACEUTICALS
INC.
|
|||
|
Dated:
June 10, 2009
|
|||
|
By:
|
/s/
Nadav Kidron
|
||
|
Nadav
Kidron
|
|||
|
President,
CEO and Director
|
|||
Oramed
Pharmaceuticals to Present at the 8th National Life Science &
Technology
Week ILSI-BIOMED Conference, Israel 2009
JERUSALEM,
Israel – June 10, 2009 – Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB; www.oramed.com),
a developer of oral delivery systems, announced that Oramed was chosen to
present at the 8th National Life Science & Technology Week ILSI-BIOMED
Conference, Israel 2009. The presentation will be given by Mr. Nadav
Kidron, President and CEO of Oramed, on Tuesday, June 16th during
the BioPharma Session at 12:30 p.m. (local time) at the David Intercontinental
Hotel in Tel-Aviv, Israel.
“The selection of Oramed as one
of the companies to present at the ILSI-Biomed is a great opportunity that
allows us to present our company to the leading biomedical, health care and life
science professionals from all over the world,” said Nadav Kidron, Oramed CEO.
For more information about the upcoming
ILSI Biomed conference, please visit http://www2.kenes.com/biomed/Pages/Home.aspx
About
Oramed Pharmaceuticals
Oramed
Pharmaceuticals is a technology pioneer in the field of oral delivery solutions
for drugs and vaccines presently delivered via injection. Oramed is
seeking to revolutionize the treatment of diabetes through its patented flagship
product, an orally ingestible insulin capsule currently in phase 2 clinical
trials. Established in 2006, Oramed’s technology is based on over 25 years of
research by top research scientists at Jerusalem’s Hadassah Medical Center. The
Company’s corporate and R&D headquarters are based in
Jerusalem.
For more
information, please visit www.oramed.com
Forward-looking
statements
Some of
the statements contained in this press release are forward-looking statements
which involve known and unknown risks, uncertainties and other factors which may
cause the actual results, performance or achievements of the company, or
industry results, to be materially different from any future results,
performance or achievements expressed or implied by such forward looking
statements, including the risks and uncertainties related to the progress,
timing, cost, and results of clinical trials and product development programs;
difficulties or delays in obtaining regulatory approval for our product
candidates; competition from other pharmaceutical or biotechnology companies;
and the company’s ability to obtain additional funding required to conduct its
research, development and commercialization activities. Please refer to the
company’s filings with the Securities and Exchange Commission for a
comprehensive list of risk factors that could cause actual results, performance
or achievements of the company to differ materially from those
expressed or implied in such forward looking statements. The company undertakes
no obligation to update or revise any forward-looking statements.
Company
and Business Development Contacts:
Oramed
Pharmaceuticals
Tara
Horn
Office: +
972-2-566-0001
Email: tara@oramed.com